Corcept Therapeutics (CORT) Gross Profit (2016 - 2025)
Historic Gross Profit for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $203.0 million.
- Corcept Therapeutics' Gross Profit rose 1300.26% to $203.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $727.8 million, marking a year-over-year increase of 1762.13%. This contributed to the annual value of $664.2 million for FY2024, which is 3956.01% up from last year.
- According to the latest figures from Q3 2025, Corcept Therapeutics' Gross Profit is $203.0 million, which was up 1300.26% from $191.0 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Gross Profit ranged from a high of $203.0 million in Q3 2025 and a low of $78.2 million during Q1 2021
- Over the past 5 years, Corcept Therapeutics' median Gross Profit value was $116.1 million (recorded in 2023), while the average stood at $128.7 million.
- As far as peak fluctuations go, Corcept Therapeutics' Gross Profit tumbled by 1444.69% in 2021, and later soared by 4733.1% in 2024.
- Corcept Therapeutics' Gross Profit (Quarter) stood at $97.5 million in 2021, then rose by 4.21% to $101.6 million in 2022, then skyrocketed by 31.46% to $133.5 million in 2023, then surged by 34.0% to $178.9 million in 2024, then rose by 13.47% to $203.0 million in 2025.
- Its Gross Profit stands at $203.0 million for Q3 2025, versus $191.0 million for Q2 2025 and $154.8 million for Q1 2025.